Our study systematically investigated DLL3 expression in a comprehensive cohort of 1294 NEN and 479 non-neuroendocrine carcinomas, revealing significant differences not only between NEC and NET in general, but also among their various histological subtypes, grades, and anatomic localisations. The gene discussed is DLL3; the disease is neuroendocrine carcinoma.